BBC
Virtus LifeSci Biotech Clinical Trials ETF [BBC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BBC Stock Summary
Top BBC Correlated Resources
BBC
Top 10 Correlated ETFs
BBC
Top 10 Correlated Stocks
BBC
In the News
BBC Financial details
Company Rating
-
Market Cap
11.64M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.08
Dividend %
0.31%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
4.55%
SMA50
15%
SMA100
43.75%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.88-31.99
52W High
-25.08%
52W Low
+45.16%
RSI
58
Rel Volume
4.39
Avg Volume
4.55K
Volume
19.98K
Perf Week
0.63%
Perf Month
6.98%
Perf Quarter
14.58%
Perf Half Y
21.09%
-
-
-
-
Beta
0.93
-
-
Volatility
0.22%, 0.61%
Prev Close
2.31%
Price
23.225
Change
3.31%
BBC Financial Performance
BBC Frequently Asked Questions
What is Virtus LifeSci Biotech Clinical Trials ETF stock symbol ?
Virtus LifeSci Biotech Clinical Trials ETF is a US stock and trading under the symbol BBC
What is Virtus LifeSci Biotech Clinical Trials ETF stock quote today ?
Virtus LifeSci Biotech Clinical Trials ETF stock price is $23.225 today.
Is Virtus LifeSci Biotech Clinical Trials ETF stock public?
Yes, Virtus LifeSci Biotech Clinical Trials ETF is a publicly traded company.
Company Profile
- Volume Average 4.55K
- Market Capitalization 11.64M
- Headquarters US
- IPO Date 2014-12-17
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
